SAN JOSE, Calif., Sept. 21 /PRNewswire-FirstCall/ -- BD (Becton, Dickinson and Company) , through its BD Biosciences segment, today announced the U.S. clearance and release of the BD FACSCanto(TM) flow cytometer for In Vitro Diagnostic (IVD) use. This new benchtop analyzer now supports not only life science and clinical research applications, but also the routine and complex tests performed in clinical laboratories, demonstrating BD Biosciences’ continued commitment to clinical diagnostics. The BD FACSCanto(TM) system was also CE-IVD marked and released in Europe earlier this year.
The BD FACSCanto(TM) system assists clinical labs in achieving quality data quickly and efficiently, offering users high fluorescence sensitivity, minimal sample contamination, and processing speeds of up to 10,000 events per second. Due to its unique performance characteristics, the BD FACSCanto(TM) system greatly facilitates rare event analysis, an important feature for clinical diagnostic laboratories.
“We leveraged our 30-plus years of expertise in flow cytometry in the design of the BD FACSCanto(TM) system,” said Bill Rhodes, Vice President and General Manager, BD Biosciences Immunocytometry Systems. “It incorporates many technology advances first developed in our BD(TM) LSR II expandable cell analyzer and our BD FACSAria(TM) cell sorter, and we are proud to deliver such an advanced, yet easy-to-use, system to the clinical diagnostics market.”
The BD FACSCanto(TM) system offers clinical laboratories the opportunity to increase efficiency and productivity. For example, the system has a fixed optical alignment, so users are not required to manually align lasers, and the fluidics cart holds all fluids necessary for routine operation and maintenance. The self-contained design facilitates automated cleaning, startup, and shutdown routines, allowing clinical laboratories to concentrate on what’s important-analysis and reporting of data. The system also provides automated sample loading with the BD FACS(TM) loader option, enabling walkaway sample acquisition, which provides laboratory personnel with more time to focus on other tasks.
The BD FACSCanto(TM) flow cytometry system is yet another technological innovation, now available for clinical testing, from a world leader in cell sorting and analysis.
BD is a medical technology company that serves healthcare institutions, life science researchers, clinical laboratories, industry, and the general public. BD manufactures and sells a broad range of medical supplies, devices, laboratory equipment, and diagnostic products. For the fiscal year ended September 30, 2003, BD reported total revenues of $4.528 billion.
For In Vitro Diagnostic Use. Class 1 (I) Laser Product
This press release may contain certain forward-looking statements (as defined under Federal securities laws) regarding BD’s performance, including future revenues, products and income, or events or developments that BD expects to occur or anticipates occurring in the future. All such statements are based upon current expectations of BD and involve a number of business risks and uncertainties. Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement. Factors that could cause actual results to vary materially from any forward-looking statement include, but are not limited to: competitive factors; pricing and market share pressures; changes in interest or foreign currency exchange rates; changes in BD’s sales volume and product mix; BD’s ability to achieve its cost savings objectives; difficulties inherent in product development and delays in product introductions; changes in regional, national or foreign economic conditions; increases in energy costs; fluctuations in costs and availability of raw materials and in BD’s ability to maintain favorable supplier arrangements and relationships; uncertainties of litigation; and changes in healthcare or other governmental regulation; issuance of new or revised accounting standards, as well as other factors discussed in this press release and in BD’s filings with the Securities and Exchange Commission. We do not intend to update any forward-looking statements.
BD, BD logo, and all other trademarks are the property of Becton, Dickinson and Company.
BD (Becton, Dickinson and Company)
CONTACT: Colleen White, Corporate Communications, +1-201-847-5369,colleen_white@bd.com
Web site: http://www.bd.com/
